(2006) GliZ, a transcriptional regulator of gliotoxin biosynthesis, contributes to Aspergillus fumigatus virulence
Damluji, MD, PhD, MBA Published Mar 29, 2025 The SOUL trial, published in The New England Journal of Medicine on March 29, 2025, provides new evidence that once-daily oral semaglutide reduces the risk of major adverse cardiovascular events in adults with type 2 diabetes and a history of atherosclerotic cardiovascular disease, chronic kidney disease, or both
Further, the study highlights that symptom confusion, misconceptions, and barriers to care are leaving many women without the clarity and support they need during the menopause transition
Neither hypoglycemia nor gastro-intestinal or psychiatric adverse events were reported